RadioLigand Therapy with [[sup.177]Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 16; no. 5
• Main Authors: Terroir, Marie, Lamesa, Chloé, Krim, Mehdi, Vija, Lavinia, Texier, Jean-Sébastien, Cassou-Mounat, Thibaut, Delord, Jean-Pierre, Vallot, Delphine, Courbon, Frédéric
• Format: Journal Article
• Language: English
• Published: MDPI AG 01.05.2023
• Subjects: Care and treatment; Dosage and administration; Health aspects; Prostate-specific antigen; Radiopharmaceuticals; Salivary gland tumors; Testing; France
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph16050754

Salivary gland cancers are rare tumors comprising a large group of heterogeneous tumors with variable prognosis. Their therapeutic management at a metastatic stage is challenging due to the lack of therapeutic lines and the toxicity of treatments. [[sup.177] Lu]Lu-PSMA-617 (prostate-specific membrane antigen) is a vectored radioligand therapy (RLT) initially developed to treat castration-resistant metastatic prostate cancer with encouraging results in terms of efficacy and toxicity. Many malignant cells could be treated with [[sup.177] Lu]Lu-PSMA-617 as long as they express PSMA as a consequence of androgenic pathway activation. RLT may be used when anti-androgen hormonal treatment has failed, particularly in prostate cancer. [[sup.177] Lu]Lu-PSMA-617 has been proposed in certain salivary gland cancers, though the expression of PSMA is demonstrated by a significant uptake using [[sup.68] Ga]Ga-PSMA-11 PET scan. This theranostic approach could be a new therapeutic option, warranting prospective investigation in a larger cohort. We review the literature on this subject and offer a clinical illustration of compassionate use in France as a perspective for administering [[sup.177] Lu]Lu-PSMA-617 in salivary gland cancer.